We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01720628
First Posted: November 2, 2012
Last Update Posted: November 2, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Yeşim Gedik Oğuz, Turkish Ophthalmology Society
  Purpose

Objectives: Behçet's disease (BD) is a systemic vasculitis. Since vascular endothelial dysfunction plays a prominent role in the pathogenesis of the disease, we considered angiogenic cytokines as an interesting target for investigation in BD. The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.

Design and Methods: Sixty five patients with BD and 21 healthy control subjects were included in the study. Serum angiogenin, bFGF and VEGF concentrations were determined by using in vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.


Condition Intervention
Behçet's Disease Other: serum levels of angiogenin, bFGF, VEGF

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Yeşim Gedik Oğuz, Turkish Ophthalmology Society:

Primary Outcome Measures:
  • Serum levels of angiogenin in Behçet's patients with or without ocular involvement [ Time Frame: 1 year ]
    The median serum angiogenin level was significantly higher in all patients with BD than controls (P=0.001). However there was no statistically significant difference between all patients and patients with or without ocular involvement. The mean serum bFGF and the median serum VEGF levels were higher in patients with ocular involvement than all patients, patients without ocular involvement and controls. But these differences did not reach statistical significance.


Secondary Outcome Measures:
  • Serum levels of bFGF in Behçet's patients with or without ocular involvement [ Time Frame: 1 year ]

Other Outcome Measures:
  • Serum levels of VEGF in Behçet's patients with or without ocular involvement [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
serum

Enrollment: 86
Study Start Date: November 2011
Study Completion Date: February 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Behçet's patients
Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
Other: serum levels of angiogenin, bFGF, VEGF
Behçet's patients

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Turkish patients fulfilling the international diagnostic criteria for Behçet's disease
Criteria

Inclusion Criteria:

  • age between 18-65
  • fulfilling the international diagnostic criteria for Behçet's disease

Exclusion Criteria:

  • to have another systemic disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01720628


Locations
Turkey
Ankara University, Faculty of Medicine, Department of Ophthalmology
Ankara, Turkey, 06620
Sponsors and Collaborators
Turkish Ophthalmology Society
Investigators
Study Director: ali yalçındağ * Dışkapı Yıldırım Beyazıt Training and Research Hospital, Department of Clinical Biochemistry
  More Information

Responsible Party: Yeşim Gedik Oğuz, MD, Turkish Ophthalmology Society
ClinicalTrials.gov Identifier: NCT01720628     History of Changes
Other Study ID Numbers: AFV-5813
First Submitted: October 23, 2012
First Posted: November 2, 2012
Last Update Posted: November 2, 2012
Last Verified: October 2012

Keywords provided by Yeşim Gedik Oğuz, Turkish Ophthalmology Society:
Angiogenin, Behçet's disease, bFGF, VEGF

Additional relevant MeSH terms:
Behcet Syndrome
Mouth Diseases
Stomatognathic Diseases
Uveitis, Anterior
Panuveitis
Uveitis
Uveal Diseases
Eye Diseases
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Hereditary Autoinflammatory Diseases
Genetic Diseases, Inborn
Skin Diseases, Genetic
Skin Diseases
Skin Diseases, Vascular
Angiogenin
Angiogenesis Inducing Agents
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs